Oral antioxidant supplementation does not prevent acute mountain sickness: Double blind, randomized placebo-controlled trial

QJM: An International Journal of Medicine

Volumn 102, Issue 5, 2009, Pages 341-348

  Baillie, J K ^a   Thompson, A A R ^b   Irving, J B ^c   Bates, M G D ^d   Sutherland, A I ^e   Macnee, W ^f   Maxwell, S R J ^g   Webb, D J ^g  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; PLACEBO; SILDENAFIL; THIOCTIC ACID;

ACUTE DISEASE; ADULT; ALTITUDE DISEASE; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INCIDENCE; LUNG ARTERY PRESSURE; MALE; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAVEL; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ALTITUDE SICKNESS; ANTIOXIDANTS; ASCORBIC ACID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOUNTAINEERING; STATISTICS AS TOPIC; THIOCTIC ACID; YOUNG ADULT;

EID: 65449175766     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp026     Document Type: Article

References (44)

1. Severinghaus JW, Chiodi H, Eger EI, Brandstater B, Hornbein TF. Cerebral blood flow in man at high altitude. Role of cerebrospinal fluid pH in normalization of flow in chronic hypocapnia. Circ Res 1966; 19 274-82.
2. Singh I, Khanna PK, Srivastava MC, Lal M, Roy SB, Subramanyam CS. Acute mountain sickness. N Engl J Med 1969; 280:175-84.
3. Houston CS, Dickinson J. Cerebral form of high-altitude illness. Lancet 1975; 2:758-61.
4. Sutherland AI, Morris DS, Owen CG, Bron AJ, Roach RC. Optic nerve sheath diameter, intracranial pressure and acute mountain sickness on Mount Everest: A longitudinal cohort study. Br J Sports Med 2008; 42 183-8.
5. Hackett PH, Yarnell PR, Hill R, Reynard K, Heit J, McCormick J. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and patho-physiology. JAMA 1998; 280 1920-5.
6. Chan PH, Fishman RA, Wesley MA, Longar S. Pathogenesis of vasogenic edema in focal cerebral ischemia. Role of superoxide radicals. Adv Neurol 1990; 52:177-83.
7. Maxwell SR, Thomason H, Sandler D, LeGuen C, Baxter MA, Thorpe GH, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27:484-90.
8. Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF, et al. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. Chest 2007; 131:1473-8.
9. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood- CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000; 14:691-8.
10. Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine [see comments]. N Engl J Med 1991; 325:1284-9.
11. Maggiorini M, Melot C, Pierre S, Pfeiffer F, Greve I, Sartori C, et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001; 103:2078-83.
12. Swenson ER, Maggiorini M, Mongovin S, Gibbs JS, Greve I, Mairbaurl H, et al. Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA 2002; 287:2228-35.
13. Dehnert C, Risse F, Ley S, Kuder TA, Buhmann R, Puderbach M, et al Magnetic resonance imaging of uneven pulmonary perfusion in hypoxia in humans. Am J Respir Crit Care Med 2006; 174:1132-8.
14. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95:11715-20.
15. Balagopalakrishna C, Manoharan PT, Abugo OO, Rifkind JM. Production of superoxide from hemoglobin-bound oxygen under hypoxic conditions. Biochemistry 1996; 35:6393-8.
16. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001; 90:1299-306.
17. Chao WH, Askew EW, Roberts DE, Wood SM, Perkins JB. Oxidative stress in humans during work at moderate altitude. J Nutr 1999; 129 2009-12.
18. Vasankari TJ, Kujala UM, Rusko H, Sarna S, Ahotupa M. The effect of endurance exercise at moderate altitude on serum lipid peroxidation and antioxidative functions in humans. Eur J Appl Physiol 1997; 75 396-9.
19. Pfeiffer JM, Askew EW, Roberts DE, Wood SM, Benson JE, Johnson SC, et al. Effect of antioxidant supplementation on urine and blood markers of oxidative stress during extended moderate-altitude training. Wilderness Environ Med 1999; 10:66-74.
20. Simon-Schnass I, Korniszewski L. The influence of vitamin E on rheological parameters in high altitude mountaineers. Int J Vitam Nutr Res 1990; 60:26-34.
21. Simon-Schnass I, Pabst H. Influence of vitamin E on physical performance. Int J Vitam Nutr Res 1988; 58:49-54.
22. Bailey DM, Davies B. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2001; 2:21-9.
23. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci 1989; 570:7-22.
24. Sies H. Strategies of antioxidant defense. Eur J Biochem 1993; 215:213-9.
25. Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on α-tocopherol. Biochim Biophys Acta 1989; 1001:256-61.
26. The Lake Louise Consensus on the Definition and Quantification of Altitude Illness. In: Coates G, Houston CS, eds. Hypoxia and Mountain Medicine. Burlington/Vermont, Queen City Printers, 1992.
27. Baillie JK, Thompson AAR, Bates MGD, Schnopp MF, Simpson A, Partridge RW. The Chacaltaya High Altitude Laboratory. J R Coll Physicians Edinb 2004; 34:130-3.
28. Wagner DR, Tatsugawa K, Parker D, Young TA. Reliability and utility of a visual analog scale for the assessment of acute mountain sickness. High Alt Med Biol 2007; 8:27-31.
29. l'Ava-Santucci J, Dessanges JF, nh Xuan AT, Lockhart A. Is arterialized earlobe blood PO2 an acceptable substitute for arterial blood PO2? Eur Respir J 1996; 9:1329-30.
30. Allemann Y, Sartori C, Lepori M, Pierre S, Melot C, Naeije R, et al Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 2000; 279:H2013-6.
31. Roach RC, Bartsch P, Oelz O, Hackett PH. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and Molecular Medicine. Burlington/Vermont, Queen City Printers, 1993:272-4.
32. Thompson AA, Baillie JK, Toshner M, Maxwell SR, Webb DJ, Irving JB. Pericardial effusions in healthy lowlanders after acute ascent to high altitude. Heart 2006; 92:539-40.
33. Subudhi AW, Jacobs KA, Hagobian TA, Fattor JA, Fulco CS, Muza SR, et al. Antioxidant supplementation does not attenuate oxidative stress at high altitude. Aviat Space Environ Med 2004; 75:881-8.
34. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: The prevention of high altitude illness trial (PHAIT). Br Med J 2004; 328:797.
35. Hoshino E, Shariff R, Van Gossum A, Allard JP, Pichard C, Kurian R, et al. Vitamin E suppresses increased lipid peroxidation in cigarette smokers. J Parenter Enteral Nutr 1990; 14:300-5.
36. Androne L, Gavan NA, Veresiu IA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14:327-30.
37. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006; 29 2365-70.
38. Jialal I, Devaraj S. Antioxidants and atherosclerosis: Don't throw out the baby with the bath water. Circulation 2003; 107:926-8.
39. Ikeda Y, Mochizuki Y, Nakamura Y, Dohi K, Matsumoto H, Jimbo H, et al Protective effect of a novel vitamin E derivative on experimental traumatic brain edema in rats - preliminary study. Acta Neurochir Suppl 2000; 76:343-5.
40. Oppido PA, Delfini R, Innocenzi G, Di Giugno G, Pecori-Giraldi J, Santoro A, et al. Brain oedema and intracranial hypertension treatment by GLIAS. Acta Neurochir Suppl (Wien) 1992; 55 40-2.
41. Waypa GB, Schumacker PT. Hypoxic pulmonary vasoconstriction: Redox events in oxygen sensing. J Appl Physiol 2005; 98:404-14.
42. Wolin MS, Ahmad M, Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: Basic concepts, current controversies, and potential importance of cytosolic NADPH. Am J Physiol Lung Cell Mol Physiol 2005; 289:L159-73.
43. Weissmann N, Grimminger F, Voswinckel R, Conzen J, Seeger W. Nitro blue tetrazolium inhibits but does not mimic hypoxic vasoconstriction in isolated rabbit lungs. Am J Physiol 1998; 274(5 Pt 1): L721-7.
44. Deem S, Min JH, Moulding JD, Eveland R, Swenson ER. Red blood cells prevent inhibition of hypoxic pulmonary vasoconstriction by nitrite in isolated, perfused rat lungs. Am J Physiol Heart Circ Physiol 2007; 292:H963-70.